SLC5A2 and diabetes mellitus: In patients with diabetes, the hsCRP-lowering effect of SGLT2 inhibitors is weaker than that of GLP-1 receptor agonists, which also provide cardiovascular protection [75]; SGLT2 inhibitors are significantly more effective than GLP-1 receptor agonists in improving renal prognosis and preventing heart failure in diabetes, but they are less effective in suppressing atherosclerotic cardiovascular events.